AKEBIA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
AKEBIA THERAPEUTICS, INC. (AKBA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.25% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-05
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-06-30 was 4.25%, a 3.91% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-03-31 was 4.00%, a 8.68% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-09-30 was 4.03%, a 2.03% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-06-30 was 4.09%, a 12.23% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.38%, a 6.01% decline from fiscal 2024.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.66%, a 3.12% decline from fiscal 2023.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.81%, a 15.35% increase from fiscal 2022.
- AKEBIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.17%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.25% 10-Q · filed 2026-08-05 | 4.25% 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | 4.00% 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 4.38% 10-K · filed 2026-02-26 | |||
| 2025-09-30 | 4.03% 10-Q · filed 2025-11-10 | 4.38% 10-Q · filed 2025-11-10 | ||
| 2025-06-30 | 4.09% 10-Q · filed 2026-08-05 | 4.38% 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | 4.38% 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 4.66% 10-K · filed 2026-02-26 | |||
| 2024-09-30 | 3.95% 10-Q · filed 2025-11-10 | 4.66% 10-Q · filed 2025-11-10 | ||
| 2024-06-30 | 4.66% 10-Q · filed 2025-08-07 | 4.66% 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | 4.23% 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 4.81% 10-K · filed 2026-02-26 | |||
| 2023-09-30 | 4.55% 10-Q · filed 2024-11-07 | 4.55% 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | 3.99% 10-Q · filed 2024-08-08 | 3.99% 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | 3.57% 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 4.17% 10-K · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |